242 related articles for article (PubMed ID: 31155003)
1. Confidentiality agreements: a challenge in market regulation.
Iunes RF; Uribe MV; Torres JB; Garcia MM; Dias CZ; Alvares-Teodoro J; de Assis Acurcio F; Guerra-Junior AA
Int J Equity Health; 2019 Jun; 18(1):11. PubMed ID: 31155003
[TBL] [Abstract][Full Text] [Related]
2. Who should pay for the continuity of post-trial health care treatments?
Iunes R; Uribe MV; Torres JB; Garcia MM; Alvares-Teodoro J; de Assis Acurcio F; Junior AAG
Int J Equity Health; 2019 Jun; 18(1):26. PubMed ID: 31155007
[TBL] [Abstract][Full Text] [Related]
3. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.
Son KB
Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820
[TBL] [Abstract][Full Text] [Related]
4. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
5. Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.
Franzen N; Ziegler A; Romagnoli G; Retèl VP; Offerman TJS; van Harten WH
Cancer Res Commun; 2022 Jan; 2(1):49-57. PubMed ID: 36860697
[TBL] [Abstract][Full Text] [Related]
6. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
7. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey.
Russo P; Carletto A; Németh G; Habl C
Health Policy; 2021 Sep; 125(9):1140-1145. PubMed ID: 34253396
[TBL] [Abstract][Full Text] [Related]
8. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
Morgan SG; Vogler S; Wagner AK
Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
[TBL] [Abstract][Full Text] [Related]
9. The high price of "free" trade: U.S. trade agreements and access to medicines.
Lopert R; Gleeson D
J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
[TBL] [Abstract][Full Text] [Related]
10. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
11. Enhancing medicine price transparency through price information mechanisms.
Hinsch M; Kaddar M; Schmitt S
Global Health; 2014 May; 10():34. PubMed ID: 24885767
[TBL] [Abstract][Full Text] [Related]
12. Negotiating antiretroviral drug prices: the experience of the Andean countries.
Seoane-Vazquez E; Rodriguez-Monguio R
Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
[TBL] [Abstract][Full Text] [Related]
13. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
Shaw B; Mestre-Ferrandiz J
Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
[TBL] [Abstract][Full Text] [Related]
14. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
15. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
16. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
17. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
Dylst P; Vulto A; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
[TBL] [Abstract][Full Text] [Related]
19. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
Son KB; Lopert R; Gleeson D; Lee TJ
Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
